Pfizer's Paxlovid sales will top at $30B this year then fall over time: analysts

It's shaping up to be a banner year for sales of Pfizer’s antiviral pill Paxlovid, but the momentum from a spate of emergency nods around the world won’t last forever, one group of analysts says.